# Pizarra — PT-pseudo_575cb2819e96 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_575cb2819e96
Task: 1

Encounter: Urology - outpatient on 24 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 7.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.25 ng/mL²
  - PSA velocity: 0.39 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 28.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7299785 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.4 ng/mL. PI-RADS 5. PSAD 0.25. Prostate volume 28 mL. csPCa 0.73.

Vitals: weight 58 kg, height 175 cm, BMI 18.9, BP 137/80 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Persistent elevation of prostate-specific antigen levels necessitates clinical reassessment after an earlier Negative biopsy.

History: A 67-year-old retired firefighter initially entered the clinical pathway three years ago after a routine screening flagged an elevated prostate-specific antigen value. He has navigated Type 2 diabetes for more than ten years using metformin and empagliflozin, maintaining recent hemoglobin A1c measurements near 58 mmol/mol. A previous systematic transrectal ultrasound biopsy returned entirely benign tissue. Urinary complaints are minimal, scoring just 1 point on the International Prostate Symptom Score questionnaire. He abstains completely from alcohol and walks for twenty minutes every day. Married and Lives with partner in a ground-floor apartment, he previously opted out of prostate cancer research trials. His surgical background includes a laparoscopic cholecystectomy performed in 2015, alongside occasional mild knee discomfort stemming from his former occupational duties. He remains a Non-smoker. While the recent magnetic resonance imaging results have prompted some concern, he continues to prioritize his daily fitness regimen.

Physical examination: DRE — texture: smooth and symmetric; size: normal; consistency: firm; mobility: unrestricted; asymmetry: none. General inspection reveals a well-nourished individual with a body mass index of 18.9. Blood pressure measures 137/80 mmHg, and the cardiac rhythm remains regular at 69 beats per minute. No abdominal masses or peripheral lymphadenopathy are detectable upon palpation.

Patient info: retired firefighter; Married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 1/35 (mild LUTS).


Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.86 +/- 0.06   (95% CI 0.74-0.98)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.06  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.58 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to change the decision regarding biopsy?
  - previous_notes (get_previous_notes) -> What was the prior management plan and what was agreed upon with the patient?

This case hinges on the findings from the retrieved documents, specifically the mpMRI prose, PSA trajectory, and prior management context, to determine if the guideline criterion for re-biopsy is met. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which included PSA 7.4 ng/mL, PI-RADS 5, and csPCa probability 0.73. It failed to incorporate the context that the prior biopsy was negative, which is a critical factor in the decision pathway. It also did not weigh the specific PSA velocity (0.39 ng/mL/yr) or the prior negative biopsy status against the guideline's specific criteria for re-biopsy.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.86) based on the high PI-RADS 5 and high csPCa probability. This suggestion could be wrong because the guideline criterion explicitly states *not* to repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed, suggesting the prior suggestion might over-rely on the PI-RADS score without adequately factoring in the prior negative biopsy status. The high aleatoric uncertainty (H=0.58) indicates the data itself is highly mixed, meaning the model cannot reliably distinguish between the correct and incorrect path given the conflicting inputs.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Is the PSA trend significant enough to change the decision regarding biopsy?
previous_notes - What was the prior management plan and what was agreed upon with the patient?
previous_notes - What was the prior management plan and what was agreed upon with the patient?

GUIDELINE ANCHOR
The guideline states that re-biopsy is indicated when the mpMRI shows a PI-RADS 4-5 lesion, and does not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Maastricht UMC+
The mpMRI report identifies a PI-RADS 5 lesion in the right posterior mid-gland peripheral zone, measuring 14 x 10 x 12 mm, with marked diffusion restriction and focal enhancement.
The report does not mention a comparison with a previous MRI.

get_psa_trend
The PSA trend shows values: Sep 2023: 5.8 ng/mL, Feb 2024: 7.2 ng/mL, Aug 2024: 4.0 ng/mL, Jan 2025: 7.4 ng/mL.

get_previous_notes
The previous notes document states that a prior systematic biopsy yielded Negative results for malignancy. The management context involved a sustained rise in PSA values, with a measurement of 6.2 ng/mL in September 2023.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no specific question arose from the retrieved documents that would necessitate its opening.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- mpMRI shows a PI-RADS 5 lesion, which meets the guideline criterion for re-biopsy.
- PSA trend shows a recent rise to 7.4 ng/mL, following a previous negative biopsy.

AGAINST Sampling this patient now:
- Previous biopsy was Negative.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the PI-RADS 5 finding, which aligns with the guideline criterion for re-biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 5 finding from the MRI and the recent PSA trend following a negative biopsy, strongly supports proceeding with a targeted biopsy according to the guideline criterion.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with a targeted biopsy is supported by the convergence of the statistical prior, the guideline criterion, and the retrieved evidence. The PI-RADS 5 finding from the mpMRI directly meets the guideline criterion for re-biopsy, which was the primary driver. This finding was further supported by the recent PSA trend following a prior negative biopsy, which tipped the decision toward sampling. The prior negative biopsy status was decisive in framing the need for this re-evaluation.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
